InterCure upgraded by Canaccord Genuity with a new price target
$INCR
Biotechnology: Pharmaceutical Preparations
Health Care
Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/18/2022 | $13.00 | Speculative Buy → Buy | Canaccord Genuity |
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts ar
InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German market. NEW YORK and HERZLIYA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) ("InterCure" or the "Company") today announced preliminary results for the full year of 2025. All amounts are
Agreements formalize research partnership combining InterCure's global pharmaceutical platform with Cannasoul's world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) ("InterCure" or the "Company") today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. ("Cannasoul"), a globally recognized pioneer in cannabis research and analytics
Canaccord Genuity upgraded InterCure from Speculative Buy to Buy and set a new price target of $13.00
6-K - Intercure Ltd. (0001857030) (Filer)
6-K - Intercure Ltd. (0001857030) (Filer)
6-K - Intercure Ltd. (0001857030) (Filer)
SC 13G - Intercure Ltd. (0001857030) (Subject)
NEW YORK, TORONTO, and HERZLIYA, Israel, April 03, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc)("InterCure" or the "Company") announced today that it has rescheduled its previously announced conference call to discuss the company's financial results for the full year ended December 31, 2022. The call was originally scheduled for April 3 at 4:30 P.M. (Eastren time) but has been rescheduled to April 4, at 4:30 P.M. (Eastren time) due to unforeseen circumstances which caused technical issues. Participants can access the live webcast and conference call through the following link: https://register.vevent.com/register/BIdec7603751894ebcbf0f22eca9
Record fiscal year 2022 revenue of $150 million Record fiscal year 2022 Adjusted EBITDA* of $32 million Record fiscal year 2022 net income of $17 million Generated $20 Million cash flow from operations Strong balance sheet with over $95 million cash NEW YORK, TORONTO, and HERZLIYA, Israel, March 31, 2023 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company") is pleased to announce its financial and operating results for the fourth quarter and year ended December 31, 2022. All amounts are expressed in New Israeli Shekels (NIS) or Canadian dollars ($), unless otherwise noted. Full Year 2022 Key Financial & Operating High
Record revenue of over $37 millioni in the second quarter of 2022 Representing an annual run rate of $150 million Adjusted EBITDAii for Q2 increased 90% YoY to $9 million Net income of $6 million for the Q2 of 2022 compared to $2 million in Q2 of 2021 Tenth consecutive quarter of profitable growth Eighth consecutive quarter of positive cash flow from operations $96 million cash on hand Revenue growth expected to continue in the third quarter and throughout 2022 NEW YORK and TORONTO and HERZLIYA, Israel, Aug. 15, 2022 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TSX:INCR) (TASE: INCR) ("InterCure" or the "Company") is pleased to announce its financial results